Skip to main content

Advertisement

Table 4 Outcomes for active controlled trials in bipolar mania (<6 weeks and 6–12 weeks)

From: Atypical antipsychotics in bipolar disorder: systematic review of randomised trials

   Events/total patients Event rate (%)   
Outcome Trials Treatment Active control Treatment Active control Relative Risk (95% CI) NNT (95% CI)
Less than 6 weeks [37, 42, 43]        
Efficacy        
All mono- and adjunctive therapy 3 242/487 227/466 50 49 1.0 (0.9 to 1.2) not calculated
Symptomatic remission        
All mono- and adjunctive therapy 3 137/333 126/322 41 39 1.1 (0.9 to 1.3) not calculated
Discontinuations        
All cause 4 75/346 90/338 22 27 0.8 (0.6 to 1.1) not calculated
Lack of efficacy 3 19/331 17/323 5.7 5.3 1.1 (0.6 to 2.1) not calculated
Adverse events 4 21/346 15/338 6.1 4.4 1.4 (0.7 to 2.6) not calculated
6 to 12 weeks [40-44]        
Efficacy        
All mono- and adjunctive therapy 4 394/616 353/585 64 60 1.1 (0.97 to 1.2) not calculated
Symptomatic remission        
All mono- and adjunctive therapy 4 335/616 280/585 54 48 1.1 (1.01 to 1.3) 15 (8.2 to 110)
Emergence of depression        
All mono- and adjunctive therapy 4 40/510 62/492 7.8 13 0.6 (0.4 to 0.9) 21 (12 to 99)
Discontinuations        
All cause 5 300/675 346/651 44 53 0.8 (0.8 to 0.9) 11 (7.1 to 30)
Lack of efficacy 5 119/675 94/651 18 14 1.2 (0.95 to 1.6) not calculated
Adverse events 5 68/675 132/651 10 20 0.5 (0.4 to 0.7) 9.8 (7.1 to 16)
  1. For discontinuations NNTp is shown in bold, indicating fewer events with treatment than placebo. More events with treatment than placebo, NNH, is in plain text. Active comparators were haloperidol or lithium